Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AHKIO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
MTX-13
|
|||||
| Synonyms |
MTX-13; DAY301; CB-002
Click to Show/Hide
|
|||||
| Organization |
Multitude Therapeutics (Originator);Maxis Biotech (Originator);Day One Biopharma
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Ab13
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase 7 (PTK7)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
T1000
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
sesutecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||
| Cervical cancer |
1 Trials
|
||||||||
| Endometrial cancer |
1 Trials
|
||||||||
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
||||||||
| Head and neck cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Oesophageal cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Time to Maximum Concentration (Tmax) | 0±0 | day |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose.
|
[1] |
| Time to Maximum Concentration (Tmax) | 0±0 | day |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose.
|
[1] |
| Time to Maximum Concentration (Tmax) | 0±0 | day |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose.
|
[1] |
| Time to Maximum Concentration (Tmax) | 0.04±0.06 | day |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose.
|
[1] |
| Time to Maximum Concentration (Tmax) | 0±0 | day |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose.
|
[1] |
| Time to Maximum Concentration (Tmax) | 0±0 | day |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose.
|
[1] |
| Maximum Observed Concentration (Cmax) | 447.5±12.02 | ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose.
|
[1] |
| Maximum Observed Concentration (Cmax) | 1008.5±44.55 | ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose.
|
[1] |
| Maximum Observed Concentration (Cmax) | 419.5±23.33 | ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose.
|
[1] |
| Maximum Observed Concentration (Cmax) | 897.5±27.58 | ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose.
|
[1] |
| Maximum Observed Concentration (Cmax) | 537±24.04 | ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose.
|
[1] |
| Maximum Observed Concentration (Cmax) | 1295±21.21 | ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 2672.02±776.73 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5893.05±866.64 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 2689.63±343.69 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 6254.58±40.59 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 3318.53±374.81 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 7782.81±455.72 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose, AUCinf.
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 2672.02±776.73 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5893.05±866.64 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 2689.63±343.69 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 6254.58±40.59 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 3318.53±374.81 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 7782.81±455.72 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose, AUCinf.
|
[1] |
| Volume of Distribution (Vd) | 50.01±8.9 | mL/kg |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose.
|
[1] |
| Volume of Distribution (Vd) | 49.64±5.32 | mL/kg |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose.
|
[1] |
| Volume of Distribution (Vd) | 51.38±9.06 | mL/kg |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose.
|
[1] |
| Volume of Distribution (Vd) | 46.24±5.5 | mL/kg |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose.
|
[1] |
| Volume of Distribution (Vd) | 35.91±5.74 | mL/kg |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose.
|
[1] |
| Volume of Distribution (Vd) | 32.56±0.22 | mL/kg |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose.
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 2672.02±776.73 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5893.05±866.64 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 2689.63±343.69 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 6254.58±40.59 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 3318.53±374.81 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 7782.81±455.72 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose, AUCinf.
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Elimination Half-Life (t1/2) | 7.99±1.57 | day |
MTX-13's in vivo pharmacokinetics was evaluated in H1975 tumor-bearing mice model. There was no clear difference in plasma concentration of MTX-13 and total Ab (Fig. 2G), MTX-13 is stable with a similar half-life (T1/2 7.99 ± 1.57 days) as naked Ab13 (T1/2 7.46 ± 1.04 days; Supplementary Fig. S4H).
Click to Show/Hide
|
[1] |
| Elimination Half-Life (t1/2) | 6.66±0.5 | day |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose.
|
[1] |
| Elimination Half-Life (t1/2) | 7.48±0.01 | day |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose.
|
[1] |
| Elimination Half-Life (t1/2) | 6.71±0.58 | day |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose.
|
[1] |
| Elimination Half-Life (t1/2) | 7.02±0.98 | day |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose.
|
[1] |
| Elimination Half-Life (t1/2) | 5.46±0.53 | day |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose.
|
[1] |
| Elimination Half-Life (t1/2) | 6.01±0.27 | day |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 2672.02±776.73 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5893.05±866.64 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 2689.63±343.69 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 6254.58±40.59 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 3318.53±374.81 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 7782.81±455.72 | day*ug/mL |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose, AUCinf.
|
[1] |
| Clearance (CL) | 5.86±1.7 | mL/day/kg |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, first dose.
|
[1] |
| Clearance (CL) | 5.15±0.76 | mL/day/kg |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, first dose.
|
[1] |
| Clearance (CL) | 5.62±0.72 | mL/day/kg |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, second dose.
|
[1] |
| Clearance (CL) | 4.8±0.03 | mL/day/kg |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, second dose.
|
[1] |
| Clearance (CL) | 4.55±0.51 | mL/day/kg |
The pharmacokinetic parameters of MTX-13, 15 mg/kg, third dose.
|
[1] |
| Clearance (CL) | 3.86±0.23 | mL/day/kg |
The pharmacokinetic parameters of MTX-13, 30 mg/kg, third dose.
|
[1] |
References